Justice Dept. Reclassifies Medical Marijuana to Less Dangerous Drug

Justice Department Reclassifies Medical Marijuana

The Department of Justice has ordered the immediate reclassification of marijuana. Acting Attorney General Todd Blanche announced that state-licensed medical marijuana products will now be categorized alongside less dangerous substances.

This significant policy shift places them in the same group as FDA-approved medications like certain painkillers and testosterone. This change, a first in decades, aims to reduce barriers to researching marijuana’s medical benefits.

Understanding the Reclassification

Under the new directive, marijuana is moving from a Schedule I drug to a Schedule III drug. Schedule I drugs are considered to have a high potential for abuse and no accepted medical use, like heroin. Schedule III drugs, however, have a moderate to low potential for physical and psychological dependence.

This reclassification means that FDA-approved products containing cannabis, as well as state-licensed medical marijuana, fall into this less restrictive category. The Department of Justice stated that this move is one of the most significant federal changes to marijuana policy in many years.

Impact on Research and Access

A primary goal of this reclassification is to accelerate and broaden the scope of medical research into cannabis. By moving marijuana to a Schedule III classification, the federal government is making it easier for scientists to study its potential therapeutic uses. This could lead to a better understanding of how marijuana can help treat various medical conditions.

The change is expected to expand and approve certain state programs that utilize cannabis for medicinal purposes. This is a key focus for the administration, following previous actions on psychedelics.

What This Change Does NOT Mean

It is crucial to understand the limitations of this new policy. The reclassification does not immediately legalize marijuana at the federal level. It will not affect the sentences of individuals currently incarcerated for marijuana possession offenses.

These are important distinctions to keep in mind as the news develops. The move is a step towards acknowledging marijuana’s medical potential, rather than a full legalization effort.

A Long Road to Reclassification

This effort to reclassify marijuana has been in progress for several years. The process began under the previous administration when President Biden recommended that agencies like the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) review marijuana’s scheduling.

In 2022, these agencies were asked to look into moving cannabis from Schedule I to Schedule III. The current administration is now working to fast-track this possibility.

Bureaucratic Hurdles and Future Steps

Despite the Attorney General’s order, there are still bureaucratic steps to complete. The process involves a public comment period and reviews by various government agencies. A hearing on the matter is scheduled for June 29th.

This hearing is part of the necessary procedures before the reclassification can become a final rule. The journey from recommendation to final rule can be lengthy, involving multiple stages of review and public input.

Broader Implications and Future Outlook

This reclassification signals a significant shift in federal drug policy regarding marijuana. It acknowledges the growing body of evidence supporting its medical use. While not full legalization, it opens doors for more research and potentially wider acceptance of medical cannabis programs.

The public comment period and agency reviews will be critical in determining the final outcome. The outcome of these processes will shape the future of marijuana policy in the United States.

Source: Justice Department reclassifies state-licensed medical marijuana (YouTube)